0.27
1.17%
-0.0032
Qualigen Therapeutics Inc stock is currently priced at $0.27, with a 24-hour trading volume of 147.94K.
It has seen a -1.17% decreased in the last 24 hours and a -9.94% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.277 pivot point. If it approaches the $0.269 support level, significant changes may occur.
Previous Close:
$0.2732
Open:
$0.2727
24h Volume:
147.94K
Market Cap:
$1.70M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-0.0672
EPS:
-4.02
Net Cash Flow:
$-10.30M
1W Performance:
-11.48%
1M Performance:
-9.94%
6M Performance:
-61.98%
1Y Performance:
-70.74%
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
760 918 9165
Address
2042 Corte Del Nogal, Carlsbad
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - ForexTV.com
ForexTV.com
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - GlobeNewswire
GlobeNewswire
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - Yahoo Finance
Yahoo Finance
Qualigen Therapeutics (NASDAQ:QLGN) Trading Up 6.1% - Defense World
Defense World
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA ... - Financial Post
Financial Post
Qualigen presents preclinical novel cancer inhibitors at AACR 2024 - Investing.com Australia
Investing.com Australia
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Qualigen Therapeutics Inc (QLGN) Revenue 2024
QLGN reported a revenue (TTM) of $4.79 million for the quarter ending June 30, 2022, a +0.62% rise year-over-year.
Qualigen Therapeutics Inc (QLGN) Net Income 2024
QLGN net income (TTM) was -$13.42 million for the quarter ending December 31, 2023, a +28.02% increase year-over-year.
Qualigen Therapeutics Inc (QLGN) Cash Flow 2024
QLGN recorded a free cash flow (TTM) of -$10.30 million for the quarter ending December 31, 2023, a +22.22% increase year-over-year.
Qualigen Therapeutics Inc (QLGN) Earnings per Share 2024
QLGN earnings per share (TTM) was -$2.66 for the quarter ending December 31, 2023, a +45.38% growth year-over-year.
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Cap:
|
Volume (24h):